|
1 Company |
|
1 Product |
|
1 Product |
|
0 Mechanisms of Action |
|
0 Trials |
|
4 News |
|
- | Vpriv (velaglucerase alfa) / Takeda
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease (clinicaltrials.gov) - Mar 2, 2018
P4, N=0, Withdrawn, Sponsor: Baylor Research Institute
N=23 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2021 --> Oct 2017 | Trial completion date: Jul 2021 --> Oct 2017
- | Trial completion: OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease (clinicaltrials.gov) - Jun 30, 2017
P2, N=30, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
N=23 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2021 --> Oct 2017 | Trial completion date: Jul 2021 --> Oct 2017 No longer recruiting --> Completed
- | Trial completion: Effects of Enzyme Replacement in Gaucher's Disease (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=70, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
No longer recruiting --> Completed Recruiting --> Completed
- Vpriv (velaglucerase alfa) / Takeda
New P4 trial: The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease (clinicaltrials.gov) - Aug 19, 2015
P4, N=23, Recruiting, Sponsor: Baylor Research Institute